Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 5 min ago
Peer-reviewedCC BY 4.0Molecules

Advanced Paclitaxel Delivery Systems in Oncology and Cardiovascular Medicine: Current Formulations and Emerging Technologies

  • Andreea Crețeanu1
  • Claudiu N. Lungu2
  • Eliza Gratiela Popa1
  • Liliana Mititelu Tartau3
  • Alina Diana Panainte4
  • Mihai Creteanu5
5 affiliations
  1. 1Department of Pharmaceutical Technology, Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
  2. 2Department of Functional and Morphological Science, Faculty of Medicine and Pharmacy, Dunarea de Jos University, 800010 Galati, Romania
  3. 3Department of Pharmacology, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
  4. 4Department of Analytical Chemistry, Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
  5. 5Department of Radiology, County Clinical Emergency Hospital, 720224 Suceava, Romania
Read full textPDFDOICite

Abstract

Oncology and cardiology use paclitaxel, a powerful cell-division inhibitor. Paclitaxel-eluting coated metal stents in oncology prevent tumor growth by modulating proliferation, apoptosis, and angiogenesis. Paclitaxel-eluting stents reduce in-stent restenosis and maintain arterial patency in cardiology. Paclitaxel encapsulated in liposomes improves targeted administration, pharmacokinetics, and therapeutic efficacy. Liposome-loaded paclitaxel has a stronger anti-tumor effect than standard formulations. Paclitaxel plus sirolimus in a stent may synergistically prevent restenosis and inhibit tumors. Liposomal formulations with supplemental medications offer promising prospects for improving therapeutic accuracy and efficacy. Liposomal paclitaxel enhances targeted drug delivery, which may improve cancer treatment and cardiovascular treatments such as drug-eluting stents and drug-coated balloons in interventional radiology. Advanced delivery technologies have changed paclitaxel drug delivery methods for therapeutic use by overcoming its low solubility and systemic toxicity. Nanocrystals and liposomes enable high drug loading and precise targeted delivery, and, by eliminating toxic solvents such as Cremophor EL, they improve the safety and efficacy of cancer therapy.

Related

  1. Machine Learning Optimization of Polymeric Complex Coacervate Micelles Reveals Cell-Type-Specific Formulations for Enhanced mRNA Delivery
    Sidharth Panda, Theresa M. Reineke
    ChemRxivPreprintLicence not statedGeneral chemistryChemRxiv
  2. Theranostic silica nanoparticles for selective and simultaneous delivery of paclitaxel and coumarin to hypoxic tumors
    Paula Rodrigo-Martínez, Lamiaa Mohamed Ahmed Ali, Carmen Coll +5
    International Journal of PharmaceuticsPeer-reviewedCC BY-NC-NDMaterials & polymersHAL
  3. Pluronic F-127-functionalized magnetic ternary hybrid nanoparticles for co-delivery of paclitaxel and psoralen: a synergistic strategy to overcome multidrug resistance in triple-negative breast cancer
    Qian Liu, Fengjie Liu, Panpan Wang +8
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textMaterials & polymersCrossrefPMC
  4. Single Cell Proteomics to Spatial Multiomics in Cardiovascular Disease: Foundations, Technologies, and Biological Insights
    Aleksandra Binek, Peggi M. Angel
    Circulation researchPeer-reviewedLicence not statedFull text2 citedPhysical chemistryPMC
  5. Advanced Flooring Technologies for Industrial and Commercial Buildings: A Critical Review of Materials, Performance, Durability, Design and Sustainability
    Artemis Kontiza, Maria Pastrafidou, Ioannis Kartsonakis
    PolymersPeer-reviewedCC BY 4.0Materials & polymersCrossref

Cite

BibTeXRIS
BibTeX
@article{crețeanu2026advanced,
  title = {{Advanced Paclitaxel Delivery Systems in Oncology and Cardiovascular Medicine: Current Formulations and Emerging Technologies}},
  author = {Andreea Crețeanu and Claudiu N. Lungu and Eliza Gratiela Popa and Liliana Mititelu Tartau and Alina Diana Panainte and Mihai Creteanu},
  journal = {Molecules},
  year = {2026},
  month = oct,
  doi = {10.3390/molecules31203652},
  url = {https://www.mdpi.com/1420-3049/31/20/3652},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Advanced Paclitaxel Delivery Systems in Oncology and Cardiovascular Medicine: Current Formulations and Emerging Technologies
AU  - Andreea Crețeanu
AU  - Claudiu N. Lungu
AU  - Eliza Gratiela Popa
AU  - Liliana Mititelu Tartau
AU  - Alina Diana Panainte
AU  - Mihai Creteanu
PY  - 2026
DA  - 2026/10/01
JO  - Molecules
DO  - 10.3390/molecules31203652
UR  - https://www.mdpi.com/1420-3049/31/20/3652
AB  - Oncology and cardiology use paclitaxel, a powerful cell-division inhibitor. Paclitaxel-eluting coated metal stents in oncology prevent tumor growth by modulating proliferation, apoptosis, and angiogenesis. Paclitaxel-eluting stents reduce in-stent restenosis and maintain arterial patency in cardiology. Paclitaxel encapsulated in liposomes improves targeted administration, pharmacokinetics, and therapeutic efficacy. Liposome-loaded paclitaxel has a stronger anti-tumor effect than standard formulations. Paclitaxel plus sirolimus in a stent may synergistically prevent restenosis and inhibit tumors. Liposomal formulations with supplemental medications offer promising prospects for improving therapeutic accuracy and efficacy. Liposomal paclitaxel enhances targeted drug delivery, which may improve cancer treatment and cardiovascular treatments such as drug-eluting stents and drug-coated balloons in interventional radiology. Advanced delivery technologies have changed paclitaxel drug delivery methods for therapeutic use by overcoming its low solubility and systemic toxicity. Nanocrystals and liposomes enable high drug loading and precise targeted delivery, and, by eliminating toxic solvents such as Cremophor EL, they improve the safety and efficacy of cancer therapy.
SN  - 1420-3049
ER  -